Cullinan Therapeutics, Inc. (CGEM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$21.31-1.75%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Cullinan is advancing its CLN-978 clinical trials for tough autoimmune diseases. The company has cash to last into 2029. Recent clinical data looks promising. Earnings beats show some progress.
Cullinan still loses money and has no revenue growth yet. Clinical trials may fail. Cash could run out before profits start.
The price is about 45% below our fair value of $33. The market expects continued losses and slow progress. We see potential if trials succeed and cash lasts.
Breaks if: Cash resources fall below level needed to fund operations into 2029
Breaks if: Trial progress stalls or clinical data fails to show benefit
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
CGEM represents a speculative growth investment focused on advancing clinical trials in autoimmune diseases. The current thesis state reflects a weakened position due to recent performance and elevated risks in the healthcare sector.
The market appears to have low expectations for CGEM, given its loss-making status and recent earnings miss. There is a low fragility tier, suggesting that while the stock is not under significant pressure, it is sensitive to changes in guidance and sector performance.
Management is actively pursuing clinical trials for multiple therapies, but the mixed results and recent earnings miss indicate uncertainty. The near-term risk of missing expectations is present, especially given the broader industry context.
The future performance of CGEM hinges on the outcomes of ongoing clinical trials and the ability to maintain momentum in a challenging market. Additionally, the company's performance will be influenced by sector trends and the results of peer companies.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss contributed to this change. Additionally, the reason to own CGEM has weakened, as its financial performance has declined.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS loss worsens beyond -$3.0 in FY26 or FY27
Over the next 1 to 3 years, CGEM's trajectory will depend on its clinical advancements and external market conditions. Not investment advice.